Payment overview · 2025
General Payments
$303.26
13 reported records · 11 companies
Healthcare provider profile · identity verified
Saad Mansoor, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1912260464
Verified facts
What the public records show
CMS Open Payments records show Saad Mansoor, M.D. received $303.26 in general payments during 2025 across 13 reported records.
Medtronic, Inc. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$65.79 | 21.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.66 | 16.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.44 | 12.3% | 2 | 2025 |
| CorMedix Inc. | Unresolved — no canonical attribution shown | $24.68 | 8.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.80 | 7.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.81 | 6.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.74 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.56 | 6.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.89 | 5.6% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $14.61 | 4.8% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $14.28 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $303.26 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SIGNIA Normalized: signia |
Device | Medtronic, Inc. | $65.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.66 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| DEFENCATH Normalized: defencath |
Drug | CorMedix Inc. | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 656 | 272 |
| Amlodipine Besylate | Amlodipine Besylate | 310 | 128 |
| Eliquis | Apixaban | 309 | 121 |
| Gabapentin | Gabapentin | 306 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 302 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 139 |
| Lisinopril | Lisinopril | 264 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 260 | 105 |
| Furosemide | Furosemide | 229 | 120 |
| Tamsulosin Hcl | Tamsulosin Hcl | 218 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 212 | 98 |
| Trazodone Hcl | Trazodone Hcl | 208 | 75 |
| Losartan Potassium | Losartan Potassium | 189 | 89 |
| Sertraline Hcl | Sertraline Hcl | 174 | 64 |
| Donepezil Hcl | Donepezil Hcl | 167 | 51 |
| Carvedilol | Carvedilol | 162 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 162 | 112 |
| Metformin Hcl | Metformin Hcl | 159 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 72 |
| Mirtazapine | Mirtazapine | 146 | 51 |
| Tramadol Hcl | Tramadol Hcl | 136 | 91 |
| Levetiracetam | Levetiracetam | 127 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 56 |
| Potassium Chloride | Potassium Chloride | 121 | 47 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 117 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 56 |
| Nifedipine Er | Nifedipine | 110 | 57 |
| Omeprazole | Omeprazole | 108 | 47 |
| Famotidine | Famotidine | 107 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 37 |
| Memantine Hcl | Memantine Hcl | 88 | 31 |
| Buspirone Hcl | Buspirone Hcl | 86 | 37 |
| Methocarbamol | Methocarbamol | 84 | 40 |
| Enoxaparin Sodium | Enoxaparin Sodium | 82 | 38 |
| Ciclopirox | Ciclopirox | 80 | 59 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 37 |
| Lamotrigine | Lamotrigine | 78 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 77 | 54 |
| Montelukast Sodium | Montelukast Sodium | 76 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 60 |
| Pregabalin | Pregabalin | 74 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 39 |
| Jardiance | Empagliflozin | 72 | 24 |
| Xarelto | Rivaroxaban | 70 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 17 |
| Simvastatin | Simvastatin | 68 | 29 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 67 | 35 |
| Lactulose | Lactulose | 67 | 52 |
| Finasteride | Finasteride | 64 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 41 |
| Myrbetriq | Mirabegron | 58 | 12 |
| Latanoprost | Latanoprost | 57 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 56 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 22 |
| Prednisone | Prednisone | 52 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 24 |
| Tradjenta | Linagliptin | 52 | 11 |
| Gemtesa | Vibegron | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 40 |
| Heparin Sodium | Heparin Sodium,porcine | 49 | 24 |
| Allopurinol | Allopurinol | 48 | 22 |
| Alendronate Sodium | Alendronate Sodium | 47 | 23 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 31 |
| Januvia | Sitagliptin Phosphate | 47 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 40 |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | 11 |
| Divalproex Sodium | Divalproex Sodium | 40 | 19 |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Lorazepam | Lorazepam | 40 | 17 |
| Sucralfate | Sucralfate | 39 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 35 |
| Dapagliflozin | Dapagliflozin Propanediol | 38 | 18 |
| Spironolactone | Spironolactone | 38 | 22 |
| Cephalexin | Cephalexin | 37 | 24 |
| Levofloxacin | Levofloxacin | 37 | 32 |
| Nitroglycerin | Nitroglycerin | 37 | 32 |
| Calcium Acetate | Calcium Acetate | 36 | suppressed |
| Glipizide | Glipizide | 36 | 25 |
| Olanzapine | Olanzapine | 36 | 11 |
| Clonazepam | Clonazepam | 34 | 13 |
| Risperidone | Risperidone | 34 | suppressed |
| Baclofen | Baclofen | 33 | 14 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 14 |
| Insulin Lispro | Insulin Lispro | 32 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 18 |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 14 |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 24 |
| Alprazolam | Alprazolam | 28 | 16 |
| Bumetanide | Bumetanide | 28 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 27 | 18 |
| Glucagon Emergency Kit | Glucagon | 26 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 26 |
| Synjardy | Empagliflozin/Metformin Hcl | 26 | suppressed |
| Trimethoprim | Trimethoprim | 26 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 25 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | 18 |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 25 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 22 |
| Torsemide | Torsemide | 24 | 17 |
| Cefdinir | Cefdinir | 23 | 19 |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | 12 |
| Lidocaine | Lidocaine | 22 | 14 |
| Meclizine Hcl | Meclizine Hcl | 22 | 14 |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | 16 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | 14 |
| Telmisartan | Telmisartan | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 15 |
| Folic Acid | Folic Acid | 18 | 15 |
| Humalog | Insulin Lispro | 17 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | 14 |
| Valsartan | Valsartan | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 14 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $303.26 · 13 records | Medtronic, Inc. | AIRSUPRA, AREXVY, CAPLYTA, DEFENCATH, Kerendia, MONOFERRIC, MOUNJARO, REPATHA, SHINGRIX, SIGNIA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error